Literature DB >> 20186817

Absence of signs of systemic involvement in four patients with bilateral multiple facial angiofibromas.

Alasdair G W Hunter1, Marjan M Nezarati, Lea Velsher.   

Abstract

Facial angiofibromas are a major diagnostic sign for tuberous sclerosis (TS) and MEN1, and the former is probably the first disease to be considered by a geneticist when such lesions are found. They occur in up to 90% of persons with TS and 40-80% of individuals with MEN1. Early onset facial angiofibromas that are not associated with any other systemic sign appear to be unusual, and their occurrence can leave the clinician with some uncertainty as to their significance, as well as how to proceed. In this article we describe four patients with what appear to be isolated, bilateral facial angiofibromas. We discuss the significance of these lesions with respect to the conditions in which they have been seen, review prior reports of apparently isolated angiofibromas, and provide some rough calculations as to how likely it would be for an underlying systemic condition to be overlooked after different levels of investigation have been performed. We also look at some aspects of the financial cost/benefit ratio of further investigation of TS beyond a clinical examination. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20186817     DOI: 10.1002/ajmg.a.33320

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis.

Authors:  Guang Yang; Lu Yang; Xiaofan Yang; Xiuyu Shi; Jing Wang; Yujie Liu; Jun Ju; Liping Zou
Journal:  Exp Ther Med       Date:  2014-11-27       Impact factor: 2.447

2.  Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type.

Authors:  Vishalakshi Viswanath; Parul Thakur; Poonam Pund
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.